Radioprotective Effects of Amifostine on Acute and Chronic Esophageal Injury in Rodents

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2, 2007, Pages 534-540

  Vujaskovic, Zeljko ^a   Thrasher, Bradley A ^a   Jackson, Isabel L ^a   Brizel, Marla B ^a   Brizel, David M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amifostine; Esophagus; Radiation; TGF

Indexed keywords

GROWTH KINETICS; HISTOLOGY; OXIDATIVE STRESS; PATHOLOGY; RADIATION EFFECTS; RATS;

AMIFOSTINE; ESOPHAGUS; HISTOPATHOLOGIC ANALYSIS;

RADIOTHERAPY;

ALPHAVBETA6 INTEGRIN; AMIFOSTINE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ESOPHAGUS INJURY; FEMALE; HISTOPATHOLOGY; IMMUNOREACTIVITY; IRRADIATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RAT;

ACUTE DISEASE; AMIFOSTINE; ANIMALS; ANTIGENS, NEOPLASM; BODY WEIGHT; CHRONIC DISEASE; DRUG EVALUATION, PRECLINICAL; ESOPHAGUS; FEMALE; INTEGRINS; MACROPHAGE ACTIVATION; MUCOUS MEMBRANE; OXIDATIVE STRESS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, INBRED F344; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548476048     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.062     Document Type: Article

References (37)

1. Block K.I., and Gyllenhaal C. Commentary: The pharmacological antioxidant amifostine-implications of recent research for integrative cancer care. Integr Cancer Ther 4 (2005) 329-351
2. Grdina D.J., Kataoka Y., and Murley J.S. Amifostine: Mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 16 (2000) 237-279
3. Utley J.F., Marlowe C., and Waddell W.J. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse 1,2. Radiat Res 68 (1976) 284-291
4. Vujaskovic Z., Feng Q.F., Rabbani Z.N., et al. Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. Radiat Res 157 (2002) 656-660
5. Yuhas J.M. Radioprotective and toxic effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) on the development of immunocompetent cells. Cell Immunol 4 (1972) 256-263
6. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
7. Kouvaris J., Kouloulias V., Kokakis J., et al. Cytoprotective effect of amifostine in radiation-induced acute mucositis-A retrospective analysis. Onkologie 25 (2002) 364-369
8. Niibe H., Takahashi I., Miyaishi K., et al. [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors]. Nippon Gan Chiryo Gakkai Shi 20 (1985) 994-1001
9. Suntharalingam M., Jaboin J., Taylor R., et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 31 (2004) 2-7
10. Cassatt D.R., Fazenbaker C.A., Bachy C.M., et al. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. Int J Radiat Oncol Biol Phys 61 (2005) 901-907
11. Ito H., Meistrich M.L., Barkley Jr. H.T., et al. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721. Int J Radiat Oncol Biol Phys 12 (1986) 211-219
12. Sagowski C., Wenzel S., Metternich F.U., et al. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: Acute and late effects. Eur Arch Otorhinolaryngol 260 (2003) 42-47
13. Ekingen G., Ozden M., Sozubir S., et al. Effect of the prostacyclin derivate iloprost in experimental caustic esophageal burn. Pediatr Surg Int 21 (2005) 441-444
14. Chung H.L., Hwang J.B., Park J.J., et al. Expression of transforming growth factor beta1, transforming growth factor type I and II receptors, and TNF-alpha in the mucosa of the small intestine in infants with food protein-induced enterocolitis syndrome. J Allergy Clin Immunol 109 (2002) 150-154
15. Buntzel J., Schuth J., Kuttner K., et al. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6 (1998) 155-160
16. Culy C.R., and Spencer C.M. Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61 (2001) 641-684
17. Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol 12 (2002) 40-45
18. Schonekas K.G., Wagner W., and Prott F.J. Amifostine-A radioprotector in locally advanced head and neck tumors. Strahlenther Onkol 175 Suppl 4 (1999) 27-29
19. Dorr W., Hamilton C.S., Boyd T., et al. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 52 (2002) 911-917
20. Keshavarzian A., Haydek J., Zabihi R., et al. Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis. Dig Dis Sci 37 (1992) 1866-1873
21. Rasey J.S., Grunbaum Z., Krohn K.A., et al. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913). Radiat Res 102 (1985) 130-137
22. Porta C., Maiolo A., Tua A., et al. Amifostine, a reactive oxygen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF. Haematologica 85 (2000) 820-825
23. Chen L., Brizel D.M., Rabbani Z.N., et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys 60 (2004) 1520-1529
24. Vujaskovic Z., Feng Q.F., Rabbani Z.N., et al. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 28 (2002) 577-590
25. Jackson IL, CL, Batinic-Haberle I, Vujaskovic Z. Superoxide dismutase mimetic reduces hypoxia-induced O2.-, TGF-beta, and VEGF production by macrophages. Free Rad Res 2007;41:8-14.
26. Vujaskovic Z., Anscher M.S., Feng Q.F., et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50 (2001) 851-855
27. Barcellos-Hoff M.H., and Dix T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10 (1996) 1077-1083
28. Rodemann H.P., Binder A., Burger A., et al. The underlying cellular mechanism of fibrosis. Kidney Int 54 Suppl (1996) S32-S36
29. Lyons R.M., Gentry L.E., Purchio A.F., et al. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110 (1990) 1361-1367
30. Riley P.A. Free radicals in biology: Oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65 (1994) 27-33
31. Sheppard D. Integrin-mediated activation of transforming growth factor-beta(1) in pulmonary fibrosis. Chest 120 (2001) 49S-53S
32. Breuss J.M., Gallo J., DeLisser H.M., et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 108 (1995) 2241-2251
33. Breuss J.M., Gillett N., Lu L., et al. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 41 (1993) 1521-1527
34. Sheppard D. Functions of pulmonary epithelial integrins: From development to disease. Physiol Rev 83 (2003) 673-686
35. Agrez M., Chen A., Cone R.I., et al. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol 127 (1994) 547-556
36. Weinacker A., Ferrando R., Elliott M., et al. Distribution of integrins alpha v beta 6 and alpha 9 beta 1 and their known ligands, fibronectin and tenascin, in human airways. Am J Respir Cell Mol Biol 12 (1995) 547-556
37. Munger J.S., Huang X., Kawakatsu H., et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96 (1999) 319-328